Ingevity EPS NGVT
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- $1.47
- Latest quarter, Q2 FY26
- $1.00
- Fiscal year 2025
- −$4.65
Ingevity's earnings per share was $1.47 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $1.00.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.65 | n/a |
| FY2024 | −$11.83 | n/a |
| FY2023 | −$0.21 | −104% |
| FY2022 | $5.48 | +87% |
| FY2021 | $2.93 | −33% |
| FY2020 | $4.37 | +1% |
| FY2019 | $4.34 | +9% |
| FY2018 | $3.97 | +34% |
| FY2017 | $2.97 | +254% |
| FY2016 | $0.84 | −56% |
| FY2015 | $1.89 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.00 | n/a | $1.47 | |
| Q1 FY26 | $1.66 | +196% | −$3.55 | |
| Q4 FY25 | −$2.37 | −615% | −$4.65 | |
| Q3 FY25 | $1.18 | n/a | −$1.82 | |
| Q2 FY25 | −$4.02 | n/a | −$5.94 | |
| Q1 FY25 | $0.56 | n/a | −$9.73 | |
| Q4 FY24 | $0.46 | n/a | −$11.83 | |
| Q3 FY24 | −$2.94 | −526% | −$15.51 | |
| Q2 FY24 | −$7.81 | −905% | −$11.88 | |
| Q1 FY24 | −$1.54 | −214% | −$3.10 | |
| Q4 FY23 | −$3.22 | −885% | −$0.21 | |
| Q3 FY23 | $0.69 | −65% | $3.42 |
Against its peers
Companies in Chemicals nearest Ingevity's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NGVTIngevity | $1.47 | |
| IOSPInnospec | $4.90 | +545% a year |
| ROGRogers | $1.75 | |
| FULFuller H B | $3.59 | +72% a year |
| WDFCWD 40 | $6.58 | +4% a year |
| AVNTAvient | $1.85 | +43% a year |
| CBTCabot | $3.54 | −54% a year |
| CRONCronos | $0.20 | +300% a year |
| CSWCSW Industrials | $7.29 | −13% a year |
| BCPCBalchem | $5.09 | +16% a year |
| HXLHexcel | $1.99 | +84% a year |
| Peer median | $3.56 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Ingevity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.